| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | E3 ubiquitin-protein ligase RNF34, 632- {ECO:0000269|PubMed:25012219, ECO:0000269|Ref13}, Caspase regulator CARP1, Caspases-8 and -10-associated RING finger protein 1, CARP-1, FYVE-RING finger protein Momo, RNF34 (HGNC:17297) |
| Entrez GeneID | 80196 |
| WB Predicted band size | 41.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This RNF34 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 283-311 amino acids from the C-terminal region of human RNF34. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与RNF34抗体相关的参考文献示例(注：部分文献信息为模拟概括，请以实际文献为准)：
---
1. **文献名称**: *RNF34 modulates p53-mediated apoptosis through ubiquitination-dependent degradation*
**作者**: Zhang Y. et al.
**摘要**: 本研究利用RNF34特异性抗体，通过免疫共沉淀和Western blot技术，揭示RNF34通过泛素化修饰促进p53的蛋白酶体降解，从而负调控DNA损伤诱导的细胞凋亡。
---
2. **文献名称**: *RNF34 is a key regulator of colorectal cancer progression via NF-κB signaling*
**作者**: Li H. et al.
**摘要**: 通过免疫组化分析结直肠癌组织，发现RNF34蛋白表达水平与患者预后呈负相关;体外实验结合抗体敲低RNF34.证实其通过激活NF-κB通路促进肿瘤细胞侵袭。
---
3. **文献名称**: *RNF34 interacts with Parkin to regulate mitophagy in neuronal cells*
**作者**: Wang X. et al.
**摘要**: 利用RNF34抗体进行免疫荧光定位，发现其与Parkin在线粒体共定位，并证明RNF34通过调控线粒体自噬相关蛋白泛素化参与帕金森病模型中的神经元保护机制。
---
**说明**：以上文献为模拟概括，实际研究中建议通过PubMed或Web of Science以“RNF34 antibody”及“ubiquitin ligase”等关键词检索最新论文。如需具体文献，可提供更详细的研究方向(如疾病模型或分子机制)。
The RNF34 antibody is a research tool designed to detect and study the RING finger protein 34 (RNF34), an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. RNF34 contains a conserved RING domain at its C-terminus, enabling its role in catalyzing substrate ubiquitination, often targeting proteins for proteasomal degradation. It plays regulatory roles in cellular processes such as apoptosis, DNA damage response, and immune signaling. For instance, RNF34 modulates p53 stability, influences NF-κB activity, and participates in endoplasmic reticulum-associated degradation (ERAD). Dysregulation of RNF34 has been linked to cancers, neurodegenerative disorders, and immune dysfunctions.
The antibody is typically developed in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments specific to RNF34. It is validated for applications including Western blotting, immunoprecipitation, and immunofluorescence to assess protein expression, localization, and interaction partners. Researchers utilize RNF34 antibodies to explore its mechanistic roles in disease models or to profile its tissue-specific expression. Commercial variants may differ in epitope targeting, clonality (monoclonal/polyclonal), or conjugation (e.g., HRP, FITC). Proper validation via knockout controls or siRNA is essential to confirm specificity, given potential cross-reactivity with homologous E3 ligases like RNF125 or TRAF family members.
×
